Literature DB >> 22848271

Fusion between cancer cells and myofibroblasts is involved in osteosarcoma.

Ling Yu1, Weichun Guo, Shenghao Zhao, Fuan Wang, Yong Xu.   

Abstract

Communication between cancer cells and the microenvironment appears to be an important determinant of disease prognosis. However, the detailed mechanisms of the interactions between cancer cells and surrounding cells have yet to be clarified. Recent studies on cell fusion have indicated this interaction to be one of the driving forces in cancer progression. Fibroblasts constitute a significant component of the carcinoma stromal compartment. Many of these fibroblasts are thought to differentiate into myofibroblasts, which are characterized by a positive expression of α-smooth muscle actin. Expression of α-smooth muscle actin in osteosarcoma was evaluated, and was observed to be excessive in the multinucleated osteoclast-like giant cells in osteosarcoma tissue, indicating the possibility of cell fusion between cancer cells and myofibroblasts. In order to test the above hypothesis, we first transformed the primary mouse embryonic fibroblast cells into activated myofibroblast cells. Osteosarcoma cells were then co-cultured with mouse myofibroblast cells, and cell fusion was investigated using species-specific chromosomal markers. Expression of α-smooth muscle actin was successfully induced in primary mouse embryonic fibroblast cells. Cells fused spontaneously with a fusion rate of approximately 1-2% and fusion between more than two cells was also observed. Our study demonstrated that fusion between cancer cells and myofibroblasts may contribute to the observed multinucleated giant cells in osteosarcoma. We posit that cell fusion is a novel mechanism for the interaction between cancer cells and the microenvironment.

Entities:  

Year:  2011        PMID: 22848271      PMCID: PMC3406565          DOI: 10.3892/ol.2011.363

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas.

Authors:  Jane Bayani; Maria Zielenska; Ajay Pandita; Khaldoun Al-Romaih; Jana Karaskova; Karen Harrison; Julia A Bridge; Poul Sorensen; Paul Thorner; Jeremy A Squire
Journal:  Genes Chromosomes Cancer       Date:  2003-01       Impact factor: 5.006

2.  Spontaneous fusion between cancer cells and endothelial cells.

Authors:  K Mortensen; J Lichtenberg; P D Thomsen; L-I Larsson
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 3.  Cell fusion as a hidden force in tumor progression.

Authors:  Xin Lu; Yibin Kang
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 4.  Fibroblasts in cancer.

Authors:  Raghu Kalluri; Michael Zeisberg
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

5.  Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Adrian L Harris; Efthimios Sivridis
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction.

Authors:  Genichiro Ishii; Takafumi Sangai; Tatsuya Oda; Yasuyuki Aoyagi; Takahiro Hasebe; Naoki Kanomata; Yasushi Endoh; Chie Okumura; Yoko Okuhara; Junji Magae; Makito Emura; Takahiro Ochiya; Atsushi Ochiai
Journal:  Biochem Biophys Res Commun       Date:  2003-09-12       Impact factor: 3.575

7.  Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH.

Authors:  S Selvarajah; M Yoshimoto; O Ludkovski; P C Park; J Bayani; P Thorner; G Maire; J A Squire; M Zielenska
Journal:  Cytogenet Genome Res       Date:  2008-10-14       Impact factor: 1.636

8.  Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells.

Authors:  Pravin J Mishra; Prasun J Mishra; Rita Humeniuk; Daniel J Medina; Gabriela Alexe; Jill P Mesirov; Sridhar Ganesan; John W Glod; Debabrata Banerjee
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.

Authors:  M F Hansen; A Koufos; B L Gallie; R A Phillips; O Fodstad; A Brøgger; T Gedde-Dahl; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families.

Authors:  D E Porter; S T Holden; C M Steel; B B Cohen; M R Wallace; R Reid
Journal:  J Bone Joint Surg Br       Date:  1992-11
View more
  4 in total

Review 1.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

2.  Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Authors:  Vincent Crenn; Kevin Biteau; Jérôme Amiaud; Clotilde Dumars; Romain Guiho; Luciano Vidal; Louis-Romée Le Nail; Dominique Heymann; Anne Moreau; François Gouin; Françoise Redini
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 3.  Cell fusion in cancer hallmarks: Current research status and future indications.

Authors:  Hao-Fei Wang; Wei Xiang; Bing-Zhou Xue; Yi-Hao Wang; Dong-Ye Yi; Xiao-Bing Jiang; Hong-Yang Zhao; Peng Fu
Journal:  Oncol Lett       Date:  2021-05-16       Impact factor: 2.967

4.  Biological characterization of preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model: A multi-modality approach.

Authors:  Rama Garimella; Jeff Eskew; Priyanka Bhamidi; George Vielhauer; Yan Hong; H Clarke Anderson; Ossama Tawfik; Peter Rowe
Journal:  J Bone Oncol       Date:  2013-02       Impact factor: 4.072

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.